Nexstim Plc · OMXHEX:NXTMH
Nexstim — Shareholder Meeting (March 2015)
17 slides from Nexstim's shareholder meeting presentation, March 2015
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Janne Huhtala | CEO | Nexstim AGM March 2015 @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj FORWARD-LOOKING STATEMENTS (“Nexstim” or the “Company”). In connection with any presentation or review of this This document may contain forward-looking statements that reflect the Company’s c
Slide 3: Nexstim at a glance
Nexstim at a glance ● Finnish Medtech in Neuromodulation ● Targeting Unmet Need in Stroke Rehabilitation ● Proprietary e-Field based Navigation as Differentiator ● Clear Execution Strategy and Global Growth Opportunity Strongly Positioned with IPR and Clinical Evidence to Non-invasive Neuromodulatio
Slide 4: 2014 Highlights
2014 Highlights IPO Dual listing of Nexstim Stroke Rehabilitation Phase II Shares in Nasdaq First North in Data published in International Helsinki and Stockholm Stroke Conference Q4 Q1 2014 Highlights NBS 5 release; the latest Pivotal Phase III, NICHE Trial, generation of e-Field based Q3 Q2 Starte
Slide 5: Stroke Therapy
Stroke Therapy Huge Unmet Need and Commercial Opportunity 5
Slide 6: Nexstim – Targeting a paradigm shift in stroke rehabilitation
Nexstim – Targeting a paradigm shift in stroke rehabilitation Nexstim’s Nexstim’sNavigated NavigatedBrain BrainTherapy® Therapy®solution (NBT) Targeting Targetingaablockbuster blockbustermarket… market for stroke solution rehabilitation for stroke rehabilitation (market for post-acute stroke treatme
Slide 7: NBT® for stroke rehabilitation – How it works
NBT® for stroke rehabilitation – How it works Validated e-Field Navigation gives Competitive Edge Using a patient’s own MRI scan as a guide, Nexstim Because the injured side is no longer dominated by provides precisely targeted, personalized, the healthy side of the brain, it is more responsive magn
Slide 8: Efficacy demonstrated in Phase II trial
Efficacy demonstrated in Phase II trial Change in upper extremity Fugl-Meyer score from baseline Trial outcome: Absolute average improvement of 20 13.8 Fugl-Meyer scores 15 P<0.05 = difference of "holding an object" and "buttoning a shirt" 84% responder rate (above "MCID" for NBT® group) 10 Differen
Slide 9: Nexstim's unique technology provides distinct benefits
Nexstim’s unique technology provides distinct benefits Integration of TMS and navigation Several distinct benefits Enhanced limb move ● TMS-navigation integration ● Improved accuracy ● Substantially improved hand ● Navigation is the key differentiator ● Dosing precision movement after treatment ● Re
Slide 10: Highlights in Stroke Rehabilitation (NBT®)
Highlights in Stroke Rehabilitation (NBT®) – 2.1m strokes each year in the US and Europe Huge unmet need – Stroke is the leading cause of long-term disability in Western world – While current standard treatment of physical/occupational therapy is not very Few effective alternatives effective, $8.5bn
Slide 11: Current Status and Outlook
Current Status and Outlook Progressing as Planned with Milestones 11
Slide 12: Phase III trials - Laying the groundwork for commercialisation
Phase III trials - Laying the groundwork for commercialisation Study in brief Study goals Conducted at 12 top US rehab sites ● Establish clinical efficacy ● Document Rehabilitation Institute of Chicago (central site) of NBT® in upper-limb effects/efficacy of TIRR Memorial Hermann Hospital (Houston)
Slide 13: Status of Clinical Development
Status of Clinical Development Progressing as Planned ● The clinical Phase III multi-center trial is progressing according to plans. The next interim analysis milestones are estimated to be reached Q3 2015 and Q1 2016 and the clinical evidence is assumed to be ready by the end of 2016 ● In addition,
Slide 14: IP position
IP position 62 granted patents 69 pending patents Right to software: Nexstim owns rights to its NBT® and NBS Systems’ software developed in- house. Creating hurdles for competitors: e.g. by seeking patent protection on different parts of the products and making it more difficult for potential compet
Slide 15: Financials
Financials Revenue Growth EUR in thousands H2 2014 H2 2013 FY 2014 FY 2013 from Device Sales with CAPEX 6 months 6 months 12 months 12 months Net sales Business Model 1,796.5 1,371.7 2,210.4 1,871.0 Personnel expenses -2,018.3 -1,492.5 -3,660.2 -3,043.4 Depreciation and amortisation -252.1 -96.0 -37
Slide 16: Summary and Outlook
Summary and Outlook Targeting a Paradigm Shift in Stroke Rehabilitation ● World-leading medical technology and software with game changing potential in stroke rehabilitation ● Good progress since IPO – business on track ● Based on its business forecast and sensitivity analysis the company expects it
Slide 17: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Thank You! @NexstimOyj